Verition Fund Management
BTAI icon

Verition Fund Management’s BioXcel Therapeutics BTAI Stock Holding History

Verition Fund Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,572
Closed -$32.2K – 3205
2024
Q2 		$32.2K Buy
+1,572
New +$52.6K ﹤0.01% 2834
2023
Q2 		– Sell
-832
Closed -$249K – 2224
2023
Q1 		$249K Buy
+832
New +$355K ﹤0.01% 1638
2020
Q1 		– Sell
-1,062
Closed -$248K – 650
2019
Q4 		$248K Buy
+1,062
New +$107K ﹤0.01% 888

Other funds holding BTAI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Verition Fund Management's BTAI Position: Q3 2024 in Review

Verition Fund Management sold out of BioXcel Therapeutics (BTAI) in Q3 2024, closing a stake of 1,572 shares — an estimated $32.2K sold.

Verition Fund Management first reported a position in BTAI in Q4 2019 and held it in 3 quarters. The position peaked at $249K in Q1 2023. 49 funds tracked by Wall St. Rank hold BTAI as of Q3 2024.

  • Verition Fund Management reported no remaining BioXcel Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Verition Fund Management sold 1,572 BioXcel Therapeutics shares in Q3 2024, an estimated $32.2K.
  • Verition Fund Management first reported a position in BioXcel Therapeutics in Q4 2019 and held it in 3 quarters.
  • Verition Fund Management's BioXcel Therapeutics position peaked at $249K in Q1 2023.
  • 49 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2024.

Based on Verition Fund Management's 13F filing for Q3 2024, filed 14 Nov 2024.